Stress, depression, the immune system, and cancer

Reiche, Edna Maria Vissoci; Nunes, Sandra Odebrecht Vargas; Morimoto, Helena Kaminami

doi:10.1016/s1470-2045(04)01597-9

Cited by 1,041 publications

(815 citation statements)

References 69 publications

Supporting

Mentioning

758

Contrasting

Unclassified

Order By: Relevance

“…Finally, it is well known that the persistent activation of the hypothalamic-pituitary-adrenal (HPA) axis as seen for example in the chronic stress response and in depression may impair the immune response and contribute to the development and progression of some types of cancer (42). Our data indicate that in endocrine system in addition to ACTH also SexH may play an important role.…”

Section: Discussionmentioning

confidence: 99%

Pituitary sex hormones enhance the pro-metastatic potential of human lung cancer cells by downregulating the intracellular expression of heme oxygenase-1

Abdelbaset‐Ismail

Pędziwiatr

Schneider

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

We report that human lung cancer cell lines express functional receptors for pituitary sex hormones (SexHs) and respond to stimulation by follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin (PRL). Expression of these receptors has also been confirmed in patient lung cancer samples at the mRNA level. Stimulation of human lung cancer cell lines with FSH, LH, or PRL stimulated migration and chemotaxis, and some cell lines responded by enhanced proliferation. Moreover, priming of human lung cancer cells by exposing them to pituitary SexHs resulted in enhanced seeding efficiency of injected human lung cancer cells into bone marrow, liver, and lungs in an immunodeficient mouse model. The chemotaxis of lung cancer cell lines corresponded with the activity of heme oxygenase-1 (HO-1), as stimulation of these cells by FSH, LH, and PRL downregulated its expression in a p38 MAPK-dependent manner. Moreover, while downregulation of HO-1 by the small-molecule inhibitor tin protoporphyrin (SnPP) promoted migration, upregulation of HO-1 by the small-molecule activator cobalt protoporphyrin (CoPP) showed the opposite effect. Based on this finding, we propose that pituitary SexHs play a significant role in the pathogenesis of lung cancer, particularly when the blood level of FSH increases due to gonadal dysfunction with advanced age. Finally, we propose that upregulation of HO-1 expression by a small-molecule activator may be effective in controlling SexH-induced cell migration in lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Pituitary sex hormones enhance the pro-metastatic potential of human lung cancer cells by downregulating the intracellular expression of heme oxygenase-1

Abdelbaset‐Ismail

Pędziwiatr

Schneider

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

“…These mechanisms include impaired genetic stability, genetic predisposition, immune dysregulation, impaired clearance of oncogenic viruses, and iatrogenic causes 85, 86. Similarities in the pathologies of autoimmune diseases and cancer have been noted in studies conducted within the preceding 30 years 85, 86. Inflammatory cytokines and growth factors mediate cell proliferation, and proteinases—especially the collagenase matrix metalloproteinase‐1 (MMP‐1)—contribute to disease progression by remodeling the extracellular matrix and modulating the microenvironment 87, 88.…”

Section: Discussionmentioning

confidence: 99%

“…Inflammatory cytokines and growth factors mediate cell proliferation, and proteinases—especially the collagenase matrix metalloproteinase‐1 (MMP‐1)—contribute to disease progression by remodeling the extracellular matrix and modulating the microenvironment 87, 88. Autoimmune disorders may activate stromal cells found in these diseases and cancers 85, 86, 87, 88. MMP‐1 was originally thought to function not only to degrade interstitial collagens; in addition, novel roles for MMP‐1 have been revealed, involving G protein‐coupled receptors, namely the chemokine receptor CXCR‐4 and protease‐activated receptor‐1 (PAR‐1).…”

Section: Discussionmentioning

confidence: 99%

“…MMP‐1 was originally thought to function not only to degrade interstitial collagens; in addition, novel roles for MMP‐1 have been revealed, involving G protein‐coupled receptors, namely the chemokine receptor CXCR‐4 and protease‐activated receptor‐1 (PAR‐1). Coordination between MMP‐1 and CXCR4 or stromal‐derived factor‐1 signaling influences the behavior of activated fibroblasts in autoimmune diseases and cancers 85, 86, 87, 88. In addition, MMP‐1 is a vital part of an autocrine‐paracrine MMP‐1‐PAR‐1 signal transduction axis—a role that amplifies the potential of MMP‐1 to remodel the matrix and modify cell behavior 87, 88.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case‐control frequency‐matched study

et al. 2018

View full text Add to dashboard Cite

BackgroundRecurrent aphthous stomatitis (RAS) is considered a prophase symptom in patients with specific cancers. This study assessed the association between RAS and subsequent onset of cancer based on a nationwide population‐based database in Taiwan.Materials and MethodsWe selected study participants from the National Health Insurance Research Database from January 2000 to December 2008. Patients in the non‐RAS cohort were matched to case study patients at a 1:1 ratio through frequency matching. All participants were followed up for at least 5 years, and those who received cancer diagnoses during follow‐up were identified.ResultsAmong 52 307 patients with and 52 304 patients without RAS, the combined hazard ratio (HR) of all subsequent cancer cases was 1.3 (95% confidence interval [CI]: 1.25‐1.35, P = 0). RAS diagnosis was associated with risk for cancers of the head and neck (aHR = 2, 95% CI: 1.8‐2.3), colon (aHR = 1.2, 95% CI: 1.1‐1.4), liver (aHR = 1.1, 95% CI: 1‐1.3), pancreas (aHR = 1.4, 95% CI: 1.1‐1.7), skin (aHR = 1.4, 95% CI: 1.2‐1.7), breast (aHR = 1.2, 95% CI: 1.1‐1.4), and prostate (aHR = 1.5, 95% CI: 1.3‐1.8), as well as hematologic cancers (aHR = 1.6, 95% CI: 1.3‐1.9). A higher risk was observed for male patients (aHR = 1.35, 95% CI: 1.28‐1.42) than for female patients (aHR = 1.25, 95% CI: 1.18‐1.31) with RAS.Conclusions RAS was associated with specific cancers. Susceptible RAS patients should be screened for specific cancers.

show abstract

Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non–Small Cell Lung Cancer

et al. 2020

View full text Add to dashboard Cite

Preexisting mental health disorders (MHDs) are associated with increased mortality in people diagnosed with cancer, yet few data exist on the efficacy of interventions to mitigate this disparity. OBJECTIVE To evaluate the association of participation in mental health treatment programs (MHTPs), housing support programs, or employment support programs with stage at cancer diagnosis, receipt of stage-appropriate treatment, and mortality among patients with a preexisting MHD. DESIGN, SETTING, AND PARTICIPANTS This retrospective, population-based cohort study included 55 315 veterans in the Veterans Affairs Central Cancer Registry (VACCR) who had newly diagnosed non-small cell lung cancer (NSCLC) from

show abstract

Stress, depression, the immune system, and cancer

Cited by 1,041 publications

References 69 publications

Pituitary sex hormones enhance the pro-metastatic potential of human lung cancer cells by downregulating the intracellular expression of heme oxygenase-1

Pituitary sex hormones enhance the pro-metastatic potential of human lung cancer cells by downregulating the intracellular expression of heme oxygenase-1

Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case‐control frequency‐matched study

Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non–Small Cell Lung Cancer

Contact Info

Product

Resources

About